Acetamide

Acetamide

SCHEMBL5465637

CC(N)=O.O=C(c1ccccc1)c1ccccc1Nc1nccs1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 1/20 0.52
▸ NPC1 O15118 4/20 0.50
▸ RAB9A P51151 4/20 0.50
▸ KMT2A Q03164 4/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ LMNA P02545 3/20 0.49
▸ HPGD P15428 2/20 0.49
▸ TP53 P04637 1/20 0.49
▸ CYP1A2 P05177 1/20 0.47
▸ ALDH1A1 P00352 6/20 0.46
▸ GAA P10253 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ STAT1 P42224 1/20 0.44
▸ USP2 O75604 1/20 0.43
▸ GLA P06280 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ HSPA5 P11021 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL28893671 0.86 CYP1A2 (0.50) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL30015045 0.83 ALDH1A1 (0.54) NPC1RAB9ASMN1; SMN2LMNAHPGD
SCHEMBL28924950 0.81 CYP1A2 (0.64) SCDNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL1339188 0.80 AURKA (0.62) SCDNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL10370992 0.72 KMT2A (0.49) KMT2AMEN1LMNAHPGDCYP1A2
SCHEMBL1341111 0.71 AURKA (0.54) SCDNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL31541257 0.71 KMT2A (0.66) NPC1RAB9AKMT2AMEN1LMNA
SCHEMBL2885036 0.71 KMT2A (0.66) NPC1RAB9AKMT2AMEN1LMNA
SCHEMBL10780930 0.71 KMT2A (0.48) KMT2AHPGDALDH1A1GAAKDM4E
SCHEMBL10777664 0.70 GAA (0.51) NPC1RAB9AKMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032518-A1 Compounds and methods of use AMGEN INC. (US) 2007-02-08 — — US disclosed
EP-1478645-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS Amgen Inc. (US) 2004-11-24 — — EP disclosed
US-6822097-B1 THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS AMGEN, INC. 2004-11-23 — — US disclosed
WO-2003066630-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS AMGEN INC. (US) 2003-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032518-A1 Compounds and methods of use BAX, BAD, CASP3 SCD 445/4885NPC1 69/4885RAB9A 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback